Long-Term Mortality of 306,868 Patients with Multi-Vessel Coronary Artery Disease: CABG versus PCI

Citation

Efird, Jimmy T., Wesley T. O'Neal, Stephen W. Davies, Whitney L. Kennedy, Lada N. Alger, Jason B. O'Neal, T. Bruce Ferguson, and Alan P. Kypson. 2013. "Long-Term Mortality of 306,868 Patients with Multi-Vessel Coronary Artery Disease: CABG versus PCI." *British journal of medicine and medical research* 3 (4): 1248-1257.

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064564>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Published in final edited form as:

Br J Med Med Res. 2013 ; 3(4): 1248–1257.

Long-Term Mortality of 306,868 Patients with Multi-Vessel Coronary Artery Disease: CABG versus PCI

Jimmy T. Efird^{1,2,3,*}, Wesley T. O'Neal^{1,2,3}, Stephen W. Davies^{1,2,4}, Whitney L. Kennedy^{1,3}, Lada N. Alger², Jason B. O'Neal⁵, T. Bruce Ferguson¹, and Alan P. Kypson¹

¹East Carolina Heart Institute, Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina University, Greenville, NC, USA

²Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, NC, USA

³Center for Health Disparities Research, Brody School of Medicine, Greenville, NC, USA

⁴Department of General Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA

⁵Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Abstract

Background—Several randomized controlled trials (RCT) have reported no difference in long-term mortality between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The purpose of this pooled observational analysis was to compare recent retrospective studies examining long-term survival of patients with multi-vessel coronary artery disease undergoing CABG and PCI.

Methodology—We searched Medline for observational studies comparing long-term (>1 year) survival between CABG and PCI for the treatment of multi-vessel coronary artery disease over the past 10 years.

Results—Eight studies met inclusion criteria. A total of 306,868 patients (155,502 CABG; 151,366 PCI) were identified. Follow-up ranged from 1 to 8 years. Mantel-Haenszel combined hazard ratios (HR) for mortality demonstrated a protective benefit of CABG compared with PCI (HR=0.77, 95% CI=0.75–0.79).

Conclusion—These findings suggest a long-term survival advantage for CABG compared with PCI in patients with multi-vessel coronary artery disease.

© 2013 Efird et al.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Corresponding author: jimmy.efird@stanfordalumni.org.

Authors' contributions

All authors contributed equally in the analysis and writing of this manuscript. All authors read and approved the final manuscript.

CONSENT

Not applicable.

ETHICAL APPROVAL

Not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

Keywords

CABG; PCI; survival; long-term

1. INTRODUCTION

Coronary artery disease (CAD) is the cause of 1 in 6 deaths in the U.S. with 785,000 Americans experiencing a new myocardial infarction (MI) and 470,000 experiencing a recurrent event annually [1]. Current therapies for CAD are aimed at reducing myocardial oxygen demand and improving blood flow to poorly perfused myocardium [2].

Revascularization can be achieved with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Both methods provide acceptable symptomatic relief. PCI is an alternative to CABG for patients with clinically stable CAD that do not have left main disease and also in cases of acute coronary syndrome (ACS) and/or MI. The usefulness of PCI is less certain in patients with multi-vessel CAD [3].

Several randomized controlled trials (RCT) have compared long-term outcomes between CABG and PCI in patients with multi-vessel CAD [4–6]. These studies reported no difference in long-term survival between CABG and PCI. However, RCTs often have narrow selection criteria resulting in limited external validity. The purpose of this analysis was to compare long-term survival of CABG versus PCI by examining retrospective studies and to contrast the results with current RCTs.

2. MATERIALS AND METHODS

A Medline search from October 2002 to October 2012 included the following keywords: ‘percutaneous coronary intervention’, ‘coronary artery bypass grafting’, ‘comparison’, ‘multi-vessel’, ‘left-main coronary artery’, ‘stent’, ‘CABG’, and ‘PCI’. Reference lists of articles were reviewed for additional papers. Additionally, we performed a manual search of the table of contents of journals known to publish relevant content and contacted key researchers in the field to inquire about manuscripts in-press.

Inclusion criteria included the following: 1) Studies published in English with full text available; 2) Retrospective comparisons between CABG and PCI; 3) > 1 year of follow-up; and 4) multi-vessel CAD. Exclusion criteria included: 1) ACS/MI within 24 hours of intervention; 2) left main coronary artery disease (LMCA); 3) RCTs; and 4) studies with the main goal of a specific subpopulation comparison. Review articles, editorials, and other non-peer reviewed manuscripts or abstracts were excluded. Studies also were assessed for scientific rigor (e.g., peer reviewed, impact factor for journal), inclusion of relevant independent and outcome-related variables, appropriate sample size, statistical heterogeneity of results, validity (internal, external), similarity of hypotheses across studies, evidence of a sufficient knowledge base for statistical integration, and consistency of evidence. A scoping review was undertaken as a means of refining the specific question for the systematic integration of the studies [7]. Quality of manuscripts was assessed using a domain-based evaluation [8]. We considered studies of greater than 1 year to be “long-term.”

Two reviewers independently conducted literature searches and discrepancies were resolved by consensus. Abstracts of relevant articles were evaluated for inclusion in this study. Data concerning study characteristics and comorbid conditions were recorded.

Source information was tabulated for all studies including, publication year, country of data collection, report type, and language in which the study was published. Statistical analyses

were conducted using SAS® Software (Version 9.3, Cary, NC). Hazard ratios (HR) and 95% confidence intervals (CI) were individually plotted to visualize differences between studies. Summary HRs and 95% CIs were computed by adapting standard Mantel-Haenszel (M-H) methods for determining weighted log-normal relative effect measures [9]. Homogeneity of HRs was tested using Tarone's approximate score method [10]. Although unpublished studies were not included in the current analysis, we collected basic information on these studies when available to help determine possible publication bias (file-drawer effect). A methods moment was employed to assess the sensitivity of results to hypothetical unpublished studies [11].

3. RESULTS AND DISCUSSION

3.1 Results

A total of 424 relevant articles were identified. Fifty-seven articles were selected for further review based upon their title. Of these, 8 articles met final inclusion criteria. The selection process is outlined in Fig. 1. Study and patient characteristics are shown in Tables 1 and 2, respectively.

Our null hypothesis that heterogeneity across studies reflects random fluctuation was not rejected at the α -level = 0.05 level of statistical significance. Publication bias was not considered to be important based on a methods moment analysis.

The pooled data included 155,502 (50.7%) CABG patients and 151,366 (49.3%) PCI patients. The summary M-H HR was 0.77 (95% CI=0.75–0.79) (Fig. 2). Exclusion of the largest study did not substantively change results (HR=0.74, 95% CI=0.71–0.77).

3.2 DISCUSSION

To our knowledge, this is the first analysis to evaluate the long-term survival of patients who underwent either CABG or PCI for the treatment of multi-vessel CAD from observational studies. Our results suggest that patients undergoing CABG have increased long-term survival compared with PCI.

Generally, RCTs are considered to be the best evidence when comparing the efficacy of treatment groups while retrospective studies, which are prone to recall and selection bias, are believed to be less convincing than prospective trials [20]. However, RCTs have known barriers to patient participation and also may not generalize to the population at-large due to narrow selection criteria [21,22]. For example, the poor, minorities, females, and the elderly often are underrepresented in many clinical trials [23].

Our results are consistent with 2 recent clinical trials. In the SYNTAX trial, 3-year major adverse cardiac and cerebrovascular events (MACCE) remained significantly increased for PCI compared with CABG in patients with multi-vessel CAD [4]. However, this study did not specifically examine mortality as the primary endpoint. The FREEDOM trial, which enrolled 1,900 patients at 140 international centers, reported reduced mortality among CABG-treated patients compared with PCI [24]. In contrast to the current analysis, the FREEDOM trial was limited to diabetic patients.

3.2.1 Limitations—We did not have access to the source data for any of the studies used in this analysis. The analysis was based on effect sizes and confidence intervals obtained from published studies. Accordingly, we were unable to use random effect models for pooling the data [25].

Another limitation is that the hazard rates between groups were not parallel for all studies included in our analysis. For example, PCI was observed to have better outcomes in the first 30 days in one study, however, a survival advantage in favor of CABG was observed for the remaining 4 years of the study [19].

Analyses combining studies cannot improve the quality or reporting of the original studies [26]. Variability between studies in reporting preoperative comorbidities, demographics, and outcome measures limits the comparative ability of such analyses. Selection bias also may be a limitation of this pooled analysis. One study in our analysis, comprising 62% of the overall sample, potentially may have marginalized the impact of smaller studies [19]. Furthermore, the heterogeneity of some studies included may have limited the interpretability of our findings. However, our results remained statistically significant after excluding this study. An inherent weakness of the current study is that patients were clinically different before their respective revascularization procedure.

No differentiation was made between patients receiving drug-eluting stents (DES) and bare metal stents (BMS). DES were introduced in 2003 and their use peaked to account for 90% of PCI procedures in 2005 [27]. The studies used in this analysis were conducted during different time periods in which this technology may have varied. Additionally, we were unable to separate cardiac mortality from total mortality due to inconsistencies in the reporting of this variable across studies.

Some of the included studies were very large and their confidence intervals were narrow, making almost all differences statistically significant. However, the smallest study was not statistically significant and was the only study with a HR > 1. Because statistical significance is influenced by sample size, the results of a large study can be statistically significant without being clinically important and vice versa. The methods that we used did not distinguish between statistical and clinical significance.

4. CONCLUSION

Results from this pooled analysis of observational studies suggest that CABG is associated with increased survival compared with PCI for patients with multi-vessel CAD. Recent RCTs also have observed similar findings in specific populations (e.g., diabetics and patients with high SYNTAX scores). A motivation for our study was that RCTs typically are conducted in highly selected populations. Thus, it is important to understand how mortality would compare for the general population of people who receive CABG and PCI. However, we still recognize that results from RCTs represent a higher level of evidence than observational studies due to the ability of randomization to render compared groups similar at baseline. Future RCTs comparing revascularization procedures may benefit by selecting a broader range of patients more reflective of the general CAD population, and including minorities, persons of low socioeconomic status, and females. Furthermore, our study highlights the limitation of completely relying on RCTs to evaluate the efficacy of cardiovascular interventions.

The degree to which inferences may be drawn depends on both internal and external validity. Internal validity for a RCT is based on the integrity of methods used to select study participants, collect information, and conduct analyses, and is a building block for external validity [28]. Apart from sampling error, RCTs strive to select participants in such a manner that differences between the index and reference groups are attributed only to the hypothesized effect under investigation [28]. On the other hand, a study is externally valid if unbiased inferences can be drawn beyond the extent of the study population examined. The pooled results of the observational studies used in this current analysis, which included

patients with varying CAD severity and demographic backgrounds, satisfy external validity criteria. In contrast, this may be limited in some RCTs.

Acknowledgments

Dr. Efirdis supported in part by NIH Grant 5R34DE022272-02. The authors thank the East Carolina Heart Institute for providing resources to conduct this study. We also acknowledge Dr. Lloyd Novick in the Department of Public Health at East Carolina University for support and guidance in the writing of this manuscript. The authors also thank Dr. Katherine T. Jones for valuable comments during the writing of this manuscript and her knowledge and insight are greatly appreciated.

References

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. *Circulation*. 2012; 125(1):e2–e220. [PubMed: 22179539]
2. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2011; 57(19):e215–367. [PubMed: 21545940]
3. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2011; 124(23):2610–42. [PubMed: 22064600]
4. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. *Eur Heart J*. 2011; 32(17):2125–34. [PubMed: 21697170]
5. Park DW, Kim YH, Song HG, Ahn JM, Oh J, Kim WJ, et al. Long-term comparison of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization: 5-year outcomes from the Asan Medical Center-Multivessel Revascularization Registry. *J Am Coll Cardiol*. 2011; 57(2):128–37. [PubMed: 21211683]
6. Vieira RD, Hueb W, Gersh BJ, Lima EG, Pereira AC, Rezende PC, et al. Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial. *Circulation*. 2012; 126(11 Suppl 1):S158–63. [PubMed: 22965977]
7. Arksey H, O'Malley L. Scoping studies: Toward a methodologic framework. *Int J Soc Res Method*. 2005; 8(1):19–32.
8. Higgins, JPT.; Green, S. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, England ; Hoboken, NJ: Wiley-Blackwell; 2008.
9. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. *J Clin Epidemiol*. 1991; 44(2):127–39. [PubMed: 1995774]
10. Paul SR, Donner A. A comparison of tests of homogeneity of odds ratios in $K \times 2$ tables. *Stat Med*. 1989; 8(12):1455–68. [PubMed: 2616935]
11. Sugita M, Kanamori M, Izuno T, Miyakawa M. Estimating a summarized odds ratio whilst eliminating publication bias in meta-analysis. *Jpn J Clin Oncol*. 1992; 22(5):354–8. [PubMed: 1469797]
12. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med*. 2005; 352(21):2174–83. [PubMed: 15917382]

13. Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. *Circulation*. 2005; 112(9 Suppl):I371–6. [PubMed: 16159849]
14. Bair TL, Muhlestein JB, May HT, Meredith KG, Horne BD, Pearson RR, et al. Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry. *Circulation*. 2007; 116(11 Suppl):I226–31. [PubMed: 17846308]
15. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med*. 2008; 358(4):331–41. [PubMed: 18216353]
16. Li Y, Zheng Z, Xu B, Zhang S, Li W, Gao R, et al. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution. *Circulation*. 2009; 119(15):2040–50. [PubMed: 19349321]
17. Yan Q, Changsheng M, Shaoping N, Xiaohui L, Junping K, Qiang L, et al. Percutaneous treatment with drug-eluting stent vs bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery. *Circ J*. 2009; 73(10):1848–55. [PubMed: 19713656]
18. Wu C, Zhao S, Wechsler AS, Lahey S, Walford G, Culliford AT, et al. Long-term mortality of coronary artery bypass grafting and bare-metal stenting. *Ann Thorac Surg*. 2011; 92(6):2132–8. [PubMed: 22014747]
19. Weintraub WS, Grau-Sepulveda MV, Weiss JM, O'Brien SM, Peterson ED, Kolm P, et al. Comparative effectiveness of revascularization strategies. *N Engl J Med*. 2012; 366(16):1467–76. [PubMed: 22452338]
20. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med*. 2000; 342(25):1887–92. [PubMed: 10861325]
21. Kelsey, JL. *Methods in observational epidemiology*. 2. New York: Oxford University Press; 1996.
22. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. *J Clin Epidemiol*. 1999; 52(12):1143–56. [PubMed: 10580777]
23. King TE Jr. Racial disparities in clinical trials. *N Engl J Med*. 2002; 346(18):1400–2. [PubMed: 11986416]
24. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for Multivessel Revascularization in Patients with Diabetes. *N Engl J Med*. 2012
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7(3):177–88. [PubMed: 3802833]
26. Ioannidis JP, Lau J. Pooling research results: benefits and limitations of meta-analysis. *Jt Comm J Qual Improv*. 1999; 25(9):462–9. [PubMed: 10481815]
27. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001–2008. *JAMA*. 2011; 305(17):1769–76. [PubMed: 21540420]
28. Porta, MS. *A dictionary of epidemiology*. 5. Oxford; New York: Oxford University Press; 2008. International Epidemiological Association.

Fig. 1. Search criteria

LMCA=left main coronary artery; RCT=randomized controlled trial.

Fig. 2. Forest plot reflecting effect of CABG on total mortality compared with PCI

Forest Plot reflects HRs and 95% CIs for each individual study included in this meta-analysis. [†]Estimates were pooled from within the study. HR < 1 reflects a survival benefit for CABG; HR > 1 reflects a survival benefit for PCI. CABG=coronary artery bypass grafting; CI=confidence interval; PCI=percutaneous coronary intervention; HR=hazard ratio.

Table 1

Studies included and characteristics

Study	Year	Single/multi-center	Study length (years)	Mean follow-up PCI/CABG (Years)	N	CABG(%)	PCI (%)
Hannan et al.[12]	2005	Multi-Center	3	1.60/1.93*	59,314	62.7	37.3
Malenka et al.[13]	2005	Multi-Center	7	3.61 [†]	14,493	70.4	29.6
Bair et al.[14]	2007	Single	5	6.8/7.3	6,369	71.9	28.1
Hannan et al.[15]	2008	Multi-Center	> 1	1.56/1.59	17,400	42.7	57.3
Li et al.[16]	2009	Single	3	2.76/3.24*	3,720	50.7	49.3
Yan et al.[17]	2009	Single	2	NR	1,309	54.2	45.8
Wu et al.[18] [§]	2011	Multi-Center	8	8.0 ^{*‡}	14,470	50.0	50.0
Weintraub et al.[19]	2012	Multi-Center	5	2.63/2.82	189,793	45.4	54.6

[§] Patients in CABG and PCI groups were matched based on propensity scores.

* Median value.

[†] Mean follow-up reported for the entire study.

[‡] Non-censored follow-up reported.

CABG=Coronary Artery Bypass Grafting; PCI=Percutaneous Coronary Intervention. NR=not reported.

Table 2

Patient characteristics

Variable	Hannan [12]	Malenka [13]	Bair [14]	Hannan [15]	Li [16]	Yan [17]	Wu [18]	Weintraub [19]
Age	67.0/65.0 [†]	64.5/62.2 ^{††}	66.6/64.5 ^{††}	66.0/65.4 ^{††}	60.8/58.4 ^{††}	61.4/61.4 ^{††}	65.6/65.6 ^{††}	74.0/74.0 ^{††}
White	89.2/87.0	NR	NR	87.7/87.7	NR	NR	83.4/83.2	NR
Male	70.9/68.6	73.3/69.6	76.5/74.9	72.5/67.2	82.9/80.8	78.7/75.8	70.1/70.0	62.3/62.8
BMI	NR	NR	NR	NR	25.4/25.6	25.7/26.1	NR	NR
HTN	NR	NR	60.5/61.0	NR	65.3/61.2	58.8/68.7	NR	83.9/83.8
HLD	NR	NR	52.5/59.2	NR	44.6/38.8	181/184 ^{††}	NR	NR
DM	33.2/25.3	34.4/26.3	27.7/19.7	38.2/32.7	26.7/25.1	30.3/28.8	29.0/28.7	35.8/35.8
Smoking	NR	NR	42.9/24.7	NR	29.3/26.1	31.9/32.8	NR	11.9/12.0
CHF	19.5/11.4	16.4/7.9	16.2/10.8	15.7/10.1	8.5/6.5	NR	14.5/14.0	11.2/10.8
Prior CVA	6.9/4.4	NR	NR	17.3/7.7	18.1/13.0	10.3/10.2	10.6/10.6	16.6/16.6
PVD	13.3/6.5	18.3/10.9	NR	10.7/7.0	11.7/5.9	2.5/2.7	7.2/6.9	16.4/16.4
Prior MI	25.0/27.4	44.7/48.5	NR	47.5/33.7	44.6/43.2	32.7/26.2	45.9/45.6	24.5/24.7
RF	3.4/2.2	2.9/4.8	4.0/1.6	4.2/3.7	27.8/16.0	1.02/0.99 ^{††}	2.6/2.5	6.1/6.1
2 Vessel	30.7/80.4	49.6/86.2	NR	30.1/75.1	18.0/77.0	26.9/55.7	62.2/62.2	NR
3 Vessel	69.3/19.6	50.4/13.8	NR	69.9/24.9	82.0/23.0	73.1/44.3	37.8/37.8	NR

Data presented as CABG/PCI. Values are percentages unless stated otherwise.

[†]Median.

^{††}Mean.

NR=not reported; BMI=Body Mass Index; CABG=coronary artery bypass grafting; CHF=congestive heart failure; CVA=cerebrovascular accident; DM=diabetes; HLD=hyperlipidemia; HTN=hypertension; MI=myocardial infarction; PCI=percutaneous coronary intervention; PVD=peripheral vascular disease; RF=renal failure.